India Pharma Outlook Team | Tuesday, 28 April 2026
Akums Drugs & Pharmaceuticals Limited has announced the launch of Aztreonam-Avibactam Injection, a new antibiotic therapy designed to tackle multidrug-resistant gram-negative bacterial infections.
The move comes at a time when rising antimicrobial resistance is making many standard treatments less effective.
The newly introduced Aztreonam-Avibactam Injection is being manufactured at the company’s advanced injectable facility in Kotdwar, Uttarakhand.
The facility is equipped to handle complex formulations and follows strict global quality standards, ensuring safe and reliable production of critical therapies.
Also Read: Consumer Trust in OTC Products: The Science Behind Safety
“The rise of antimicrobial resistance has significantly reduced the effectiveness of conventional therapies,” said Sanjeev Jain, Managing Director, Akums. “Aztreonam-Avibactam represents an important advancement in addressing infections caused by highly resistant pathogens, especially where timely and effective intervention is critical.”
The therapy combines aztreonam, a monobactam antibiotic known for targeting gram-negative bacteria, with avibactam, a beta-lactamase inhibitor that prevents the breakdown of the antibiotic. This dual-action approach improves its effectiveness against resistant strains that no longer respond to traditional treatments.
“Our Kotdwar facility reflects our commitment to delivering high-quality, globally compliant pharmaceutical solutions,” said Sandeep Jain. “With advanced infrastructure, specialized manufacturing environments, and robust quality systems, we ensure that complex therapies such as Aztreonam-Avibactam are developed and produced with the highest standards of safety, efficacy, and reliability.”
The launch marks a significant step for AKUMS as it strengthens its role in addressing urgent healthcare challenges linked to antimicrobial resistance.
.jpg)
.jpg)
